Congress Blocks Federal Workers' Comp Coverage for Medical Cannabis
House committee votes to exclude medical marijuana from federal workers' compensation programs despite potential rescheduling moves.
The House Appropriations Committee advanced legislation that would explicitly prohibit federal employees from receiving medical marijuana coverage through workers' compensation programs, even as the Trump administration considers cannabis rescheduling. The committee approved the Fiscal Year 2027 Labor-HHS appropriations bill, inserting language that creates a firewall between federal benefits and state-legal medical cannabis programs.
This congressional action highlights the complex regulatory patchwork facing the cannabis industry as it seeks broader legitimacy. While 38 states have legalized medical marijuana, federal employees remain locked out of accessing these treatments through government-backed insurance programs. The prohibition affects roughly 2.2 million federal workers who might otherwise benefit from medical cannabis for workplace injuries or chronic conditions.
The timing proves particularly significant as cannabis companies navigate conflicting signals from Washington. Trump's recent statements about potential rescheduling have boosted investor sentiment across major operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF). However, this appropriations language demonstrates that even administrative rescheduling may not automatically resolve all federal-level restrictions.
For the broader cannabis market, this development underscores the incremental nature of federal reform. Multi-state operators continue generating strong cash flows from state-legal operations, but federal prohibition still limits access to traditional banking, interstate commerce, and now federal employee benefits. The industry's $30 billion annual revenue remains constrained by these regulatory barriers, despite growing state-level acceptance.
The appropriations bill must still pass the full House and Senate, where similar restrictions have appeared in previous years. Cannabis advocates view these provisions as unnecessary obstacles that prevent injured federal workers from accessing doctor-recommended treatments. As the industry matures and seeks institutional investment, these federal employment restrictions represent another hurdle in achieving full market normalization and expanded patient access across all sectors of the economy.